免疫治疗控制恶性胸腔积液的研究进展

Research progress of immunotherapy in controlling malignant pleural effusion

恶性胸腔积液(MPE)是指胸腔积液中存在经病理证实的脱落肿瘤细胞或胸膜活检组织中发现肿瘤细胞,其发生、发展与患者的预后密切相关。MPE的治疗措施分为全身治疗和胸腔内局部治疗,其中胸腔内注射治疗是治疗MPE的重要手段,包括热灌注治疗、胸腔内化疗、抗血管生成治疗和免疫治疗等,其中的胸腔内化疗和抗血管生成治疗已经取得较为显著的效果。MPE的免疫治疗具有较大的发展空间与前景,而有关免疫治疗控制MPE的临床研究较少,迫切需要更多的临床数据,本文对免疫治疗控制MPE进行综述,旨在为MPE的治疗提供多种思路,促进免疫治疗的发展。

Malignant pleural effusion(MPE)refers to the presence of pathologically confirmed shed tumor cells or tumor cells found in pleural biopsy tissue in pleural effusion,and its occurrence and development are closely related to the patient’s prognosis.The treatment measures of MPE can be divided into systemic therapy and intrathoracic local therapy,in which intrathoracic injection therapy is an important means to treat MPE,including thermal perfusion therapy,intrathoracic chemotherapy,anti-angiogenesis therapy,and immunotherapy.In them,intrathoracic chemotherapy and anti-angiogenesis therapy have achieved relatively remarkable results.Immunotherapy of MPE has a great development space and prospect,while there are few clinical researches on immunotherapy to control MPE,and more clinical data are urgently needed.Immunotherapy to control MPE is reviewed in this paper,aiming at providing a variety of ideas for the treatment of MPE and promoting the development of immunotherapy.